|
1) Nathan DM, Buse JB, Davidson MB, at el. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Associ-ation and the European Association for the Study of Diabetes. Diabetes Care. 2006; 29: 1963-72
|
|
|
|
2) The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329: 977-86
|
|
|
|
|
|
3) Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995; 28: 103-17
|
|
|
|
|
|
4) UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulpho-nylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837-53
|
|
|
|
|
|
5) American Diabetes Association. Standards of medical care in diabetes--2008. Diabetes Care. 2008; 31 Suppl 1: S12-54
|
|
|
|
|
|
6) International Diabetes Federation. Guideline for Management of Postmeal Glucose. Belgium: Lesaffre Printers; 2007
|
|
|
|
|
|
7) DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001; 161: 397-405
|
|
|
|
|
|
8) Nakagami T, Qiao Q, Tuomilehto J, et al. Screen-detected diabetes, hypertension and hyper-cholesterolemia as predictors of cardiovascular mortality in five populations of Asian origin: the DECODA study. Eur J Cardiovasc Prev Rhabil. 2006; 13: 555-61
|
|
|
|
|
|
9) Ceriello A, Quagliaro L, Piconi L, et al. Effect of postprandial hypertriglyceridemia and hyper-glycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes. 2004; 53: 701-10
|
|
|
|
|
|
10) Hanefeld M, Koehler C, Schaper F, et al. Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals. Atherosclerosis. 1999; 144; 229-35
|
|
|
|
|
|
11) Kawano H, Motoyama T, Hirashima O, et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol. 1999; 34: 146-54
|
|
|
|
|
|
12) American Heart Association; American Diabetes Association. Primary prevention of cardio-vascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Associ-ation. Diabetes Care. 2007; 30: 162-72
|
|
|
|
|
|
13) ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358: 2560-72
|
|
|
|
|
|
14) ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007; 370: 829-40
|
|
|
|
|
|
15) Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358: 2545-59
|
|
|
|
|
|
16) 日本糖尿病学会. 糖尿病治療ガイド2008-2009. 東京: 真興社; 2008
|
|
|
|
|
|
17) Massi-Benedetti M, Orsini-Federici M. Treatment of type 2 diabetes with combined therapy: what are the pros and cons？ Diabetes Care. 2008; 31 Suppl 2: S131-5
|
|
|
|
|
|
18) Kimoto K, Suzuki K, Kizaki T, et al. Gliclazide protects pancreatic beta-cells from damage by hydrogen peroxide. Biochem Biophys Res Commun. 2003; 303: 112-9
|
|
|
|
|
|
19) 下田将司, 早川尚雅, 辰巳文則, 他. 2型糖尿病薬物治療における低用量グリクラジドの有用性. 糖尿病. 2008; 51: 221-5
|
|
|
|
|
|
20) Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003; 26: 3080-6
|
|
|
|
|
|
21) Gomez-Perez FJ, Fanghanel-Salmon G, Antonio Barbosa J, et al. Efficacy and safety of rosi-glitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev. 2002; 18: 127-34
|
|
|
|
|
|
22) Weissman P, Goldstein BJ, Rosenstock J, et al. Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study. Curr Med Res Opin. 2005; 21: 2029-35
|
|
|
|
|
|
23) Bailey CJ, Bagdonas A, Rubes J, et al. Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study. Clin Ther. 2005; 27: 1548-61
|
|
|
|
|
|
24) Yki-Jarvinen H, Ryysy L, Nikkila K, et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. University of Helsinki. Ann Intern Med. 1999; 130: 389-96
|
|
|
|
|
|
25) Strowig SM, Aviles-Santa ML, Raskin P. Improved glycemic control without weight gain using triple therapy in type 2 diabetes. Diabetes Care. 2004; 27: 1577-83
|
|
|
|
|
|
26) Pioglitazone 014 Study Group. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract. 2002; 56: 251-7
|
|
|
|
|
|
27) Garg R, Gopal J, Jones GR. Rosiglitazone: safety and efficacy in combination with insulin in poorly controlled type 2 diabetes mellitus patients treated with insulin alone. J Diabetes Complications. 2007; 21: 1-6
|
|
|
|
|
|
28) Gillies PS, Dunn CJ. Pioglitazone. Drugs. 2000; 60: 333-45
|
|
|
|
|
|
29) Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007; 298: 1216-8
|
|
|
|
|
|
30) Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356: 2457-71
|
|
|
|
|
|
31) Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazo-lidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007; 370: 1129-36
|
|
|
|
|
|
32) RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med. 2007; 357: 28-38
|
|
|
|
|
|
33) Schwartz AV, Sellmeyer DE, Vittinghoff E, et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab. 2006; 91: 3349-54
|
|
|
|
|
|
34) ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide mono-therapy. N Engl J Med. 2006; 355: 2427-43
|
|
|
|
|
|
35) Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2008; 31: 173-5
|
|
|
|
|
|
36) Erlinger TP, Brancati FL. Postchallenge hyper-glycemia in a national sample of U. S. adults with type 2 diabetes. Diabetes Care. 2001; 24: 1734-8
|
|
|
|
|
|
37) Bonora E, Corrao G, Bagnardi V, et al. Prevalence and correlates of post-prandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus. Diabetologia. 2006; 49: 846-54
|
|
|
|
|
|
38) Shimoda M, Kanda Y, Tawaramoto K, et al. Molecular mechanism for proliferative effect of the once-daily human GLP-1 analog liraglutide on pancreaticβcells in diabetic db/db mice; Evidence for anti-oxidative mechanism. Diabetes. 2008; 31 Suppl: A3
|
|
|
|
|